Targeting progerin farnesylation resulted in a mild benefit in body weight, bone, and vascular alterations in a subset of HGPS patients and was associated with lower mortality rate after 2.2 years of follow-up; however, the estimated increase in life expectancy is only 1.6 years10,13–15, highlighting the limitations in translating results of preclinical mouse studies to HGPS patients. This evidence concerns the gene LMNA and Hutchinson-Gilford progeria syndrome.